Hang Seng short-term average moves up gradually and pays attention to 25000 resistance points

category:Finance
 Hang Seng short-term average moves up gradually and pays attention to 25000 resistance points


U.S. stocks were weak and volatile, while Hong Kongs ADR index was under pressure all day, closing at 24369 points, down 273 points or 1.12% on a pro rata basis. Large blue chips generally fell, with HSBC Holdings closing at HK $37.29, down HK $0.06 from Hong Kongs close, and Tencent holdings closing at HK $456.89, down HK $3.51 from Hong Kongs close.

International oil prices continued to rebound on Friday, with the market optimistic about the reduction of oil production in oil producing countries. New York oil (July) ended at $39.75 a barrel, up $0.91 or 2.34%, up nearly 10% in the whole week; Brent oil (August) ended at $42.19 a barrel, up $0.68 or 1.64%.

International gold prices rose, with New York Futures (August) closing at $1753 an ounce on Friday, up $21.9 or 1.3%, up about 0.9% for the week, and up nearly 14% this year. Goldman Sachs latest report said it believed the price of gold would reach $2000 an ounce in the next 12 months.

The Hang Seng index continued to rebound on Friday, after opening low in the morning, it was concussed and sorted out. The index rose 0.73% to 24643.9 in the afternoon, with a turnover of HK $151.46 billion.

From the perspective of the market, after three days of concussion and consolidation, the Hang Seng Index rose significantly, breaking through the 10-day average smoothly, and its short-term structure became stronger. Zooming in to the weekly level, the Hang Seng Index closed positive last week, up 342.51 points or 1.41%, and the short-term average gradually moved up. For the HSI, the short-term integer barrier 25000 points is still the first resistance level.

Summing up the performance of US stocks last week, the Dow, the standard and the NASDAQ rose 1.04%, 1.86% and 3.73% respectively. The rise in newly confirmed cases and the mixed performance of economic data in the United States have cooled the optimistic expectation of a V-shaped economic rebound. In fact, after the index rebounded nearly 40% from its low in March, the past two weeks seem to have lost momentum, and it is now vulnerable to fundamentals such as its own valuation and economic data.

Nowadays, the U.S. stock market lacks the momentum to rise, and the unknown stock soars. Retail investors outperform the fund in stock selection, which is called little devil. UBS has warned clients not to follow the trend and avoid chasing hot stocks that have been pushed into speculative frenzy by short-term traders.

On the news, the health incident has led to a sharp increase in the deposits of large US banks, which have poured into US $2 trillion so far in January. In April alone, Bank of Americas balance of deposits increased by $865 billion, more than the previous record annual increase.

The Federal Reserve has incorporated health events into this years bank stress test simulation scenario, and tested whether the banking system can cope with possible adverse economic and financial conditions by simulating three economic downside risk paths.

Therefore, for Hong Kong stocks, it is difficult to judge whether there is an independent market in the near future. But careful investors will find that the main theme is not to speculate in the stock market, and there is a certain opportunity for Hong Kong stocks to fight new and continue to be hot.

In addition, there was a major change in the Shanghai Composite Index. The plan was revised, ST shares were abandoned and incorporated into science and technology innovation board securities, which was implemented on July 22. A shares may usher in index bull. On June 22, the first batch of enterprises to be accepted in the reform of A-share gem and pilot registration system will be unveiled. Pay attention to the opportunity of revaluation of Chinese securities companies.

In terms of stocks, Yasheng pharmaceutical-b (06855) released an announcement to reach clinical cooperation with acerta pharmaceutical, AstraZeneca blood research and development center; China xinlianxin chemical fertilizer (01866) plans to introduce strategic investors to Henan xinlianxin, with the shareholding down to 76.31%; Litian film (09958) is listed today.

Source: Wang Honggui, editor in charge of Zhitong finance and Economics Network_ NF7326